The company has indicated an intent to file an IND with the FDA and a CTA with the EMA in late 2026.
Overall, the safety margin (NOAEL/anticipated human exposure) exceeds 10‑fold, supporting progression to first‑in‑human (FIH) studies. MEYD-873